Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

医学 中止 内科学 临床终点 不利影响 实体瘤疗效评价标准 临床研究阶段 黑色素瘤 无进展生存期 肿瘤科 化疗 外科 胃肠病学 临床试验 癌症研究
作者
Chuanliang Cui,Yu Chen,Zhiguo Luo,Zhengyun Zou,Yu Jiang,Hongming Pan,Qingxia Fan,Jianfu Zhao,Qing Xu,Renbing Jiang,Xuan Wang,Taiyang Ma,Zhen Guo,Lu Si,Zhihong Chi,Xinan Sheng,Yiwei Dou,Qian Tan,Di Wu,Jun Guo
出处
期刊:BMC Cancer [BioMed Central]
卷期号:23 (1) 被引量:8
标识
DOI:10.1186/s12885-022-10473-y
摘要

Abstract Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2. Methods In this phase 2 trial, patients with locally advanced or metastatic melanoma who had failed conventional treatment (chemotherapy, targeted therapy, interferon, IL-2, et al.) were recruited. The patients were administrated with Pucotenlimab of 3 mg/kg every 3 weeks until disease progression, intolerable toxicity, or treatment discontinuation for any other reasons. The primary endpoint was the overall response rate (ORR). The secondary endpoints were disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and toxicity. Results One-hundred and nineteen patients were enrolled and followed up for 19.32 (ranging from 15.901 to 24.608) months by the cutoff date of July 30 th , 2021. The ORR was 20.17% (24/119, 95% CI, 13.370%-28.506%) based on both independent review committee (IRC) and the investigator’s assessment per RECIST v1.1. The median PFS were 2.89 (95% CI, 2.037–4.074) months and 2.46 (95% CI, 2.004–4.008) months based on IRC and investigator’s assessment, respectively, per RECIST v1.1. The median OS was 16.59 (95% CI, 13.963–26.973) months. Treatment-related adverse events (TRAEs) occurred in 77.3% (92/119) of the patients. The incidence of Grade ≥ 3 TRAEs was 15.1% (18/119). In addition, none of the patients died because of TRAEs. As for biomarker analysis, Eotaxin (CCL11) and MCP-1 (CCL2) were related to treatment response, while TNF-α and VEGF were related to treatment failure. Conclusions Pucotenlimab as a ≥ 2 nd line therapy showed promising efficacy and tolerable toxicity for patients with locally advanced or metastatic melanoma. Trial registration Clinicaltrials.gov Identifier: NCT04749485 (registered retrospectively on 11/02/2021).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香蕉觅云应助momo采纳,获得10
1秒前
2秒前
3秒前
爆米花应助李春鸿采纳,获得10
6秒前
LJJ发布了新的文献求助10
7秒前
8秒前
9秒前
10秒前
10秒前
Ava应助YYH采纳,获得10
10秒前
量子星尘发布了新的文献求助10
10秒前
小田心完成签到,获得积分10
10秒前
13秒前
小田心发布了新的文献求助10
13秒前
WYH发布了新的文献求助10
14秒前
一方通行发布了新的文献求助10
14秒前
SherlockHe发布了新的文献求助10
15秒前
FashionBoy应助热情的达采纳,获得10
15秒前
18秒前
lelelele发布了新的文献求助10
19秒前
拜拜完成签到,获得积分10
20秒前
20秒前
扶苏完成签到,获得积分10
20秒前
22秒前
mmm完成签到,获得积分20
23秒前
momo发布了新的文献求助10
23秒前
23秒前
一方通行完成签到,获得积分10
23秒前
xiaosu完成签到,获得积分10
24秒前
小马甲应助yyy采纳,获得10
27秒前
热情的达发布了新的文献求助10
27秒前
Hello应助任性的咖啡采纳,获得10
28秒前
28秒前
墨墨完成签到,获得积分10
28秒前
29秒前
cangy完成签到,获得积分10
30秒前
岸部完成签到,获得积分10
30秒前
在水一方应助WYH采纳,获得10
31秒前
32秒前
搜集达人应助胡航航采纳,获得10
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173